6 Committee comments
6.1 The committee noted there are a number of different devices in use.
6.2 The committee was advised that the mesh slings are intended to be permanent implants, and that the presence of anchors makes removal of an implant, if necessary, particularly difficult.
6.3 The committee noted that, despite the existence of 2 registries, data collection had been poor and previous recommendations had not been followed.
6.4 The committee encouraged the reporting of all device-related adverse events to the Medicines and Healthcare products Regulatory Agency.
6.5 The committee was advised that a national standard consent form is being developed.
6.6 The committee noted the work of NHS England's Mesh Working Group and the Scottish Government's independent review of the use, safety and efficacy of transvaginal mesh implants in the treatment of stress urinary incontinence and pelvic organ prolapse in women.